PT-141

If you have uncontrolled hypertension or known cardiovascular disease: This is a contraindication listed on the FDA label. PT-141 causes transient increases in blood pressure after each dose. For most healthy patients this is clinically insignificant, but if your blood pressure is already poorly controlled or you have known cardiovascular disease, this additional spike — even temporary — adds risk. The FDA states PT-141 is not recommended in patients at high risk for cardiovascular disease. Your cardiologist and prescriber both need to be involved in this decision.

If you are pregnant, planning to become pregnant, or breastfeeding: Animal studies showed fetal harm at exposures greater than or equal to 16 times the maximum recommended dose. There is insufficient human safety data for pregnancy. The FDA recommends women use effective contraception while taking PT-141 and discontinue if pregnancy is suspected. There is no data on presence of bremelanotide in breast milk.

If you have significant nausea sensitivity or active GI conditions: With approximately 40% of patients experiencing nausea, this is not a minor side effect. If you have conditions that make nausea particularly problematic — hyperemesis, cyclic vomiting, or you’re taking other medications that cause nausea — the compounding effect may be intolerable.

If you are taking medications that affect blood pressure: The transient blood pressure increase from PT-141 may interact with antihypertensive medications or other drugs that affect cardiovascular function. Do not use more than one dose in 24 hours to minimize risk of compounding blood pressure effects. Discuss all current medications with your provider.

If you have a history of skin conditions sensitive to pigmentation changes: The melanocortin mechanism that drives PT-141’s sexual health effects also affects melanin production through MC1R activation. Patients with melasma, vitiligo, or other pigmentation-sensitive conditions should discuss this with their dermatologist before starting. Focal hyperpigmentation has been reported on the face, gums and breasts.

If your sexual dysfunction is caused by a medication, medical condition, or relationship factors: The FDA approval specifically covers acquired, generalized HSDD that is NOT due to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication. If your low desire has an identifiable cause, treating that cause is the appropriate first step. PT-141 is not designed to override medication side effects or mask relationship dynamics — though some practitioners do use it off-label in these contexts.

If you expect it to work like Viagra: PT-141 is not an erection drug. It works on desire and arousal through the central nervous system, not on mechanical blood flow. If your primary issue is erectile function rather than desire, PDE5 inhibitors may be more appropriate. Some providers use them in combination, but the expectations need to be set correctly.

If you have severe renal impairment: The FDA label notes that patients with severe renal impairment (eGFR below 30) may have an increase in the incidence of adverse reactions. Use with caution in this population.

The general principle: PT-141 has the unusual distinction of being both an FDA-approved drug and a compound with significant off-label use in populations where it hasn’t been rigorously studied — primarily men and postmenopausal women. The FDA approval validates the mechanism and safety profile, but the narrow approval scope means most users are accessing it off-label through compounding. A good provider will evaluate your cardiovascular health, blood pressure, current medications, and specific sexual health concerns before prescribing — not just hand you a prescription.